Pfizer is pleased to announce the call for proposals for the Global Research Awards for Nicotine Dependence (GRAND) 2017.
The overall mission of the GRAND program is to advance the pharmacological treatment of tobacco and nicotine dependence.
The GRAND program will fund at least 5 grants of between US $50,000 and US $200,000 in value, totaling US $1million.
Applications will be formally assessed by, and only by, the GRAND Review Committee, an independent committee comprising internationally prominent researchers in the field. The final responsibility for selection of Awardees rests with the Co-Chairs of the Review Committee, John Hughes and Karl Fagerstrom. The whole process is completely independent of Pfizer, including the final selection of Awardees.
GRAND is open to all investigators from around the world holding an MD, a PhD, or equivalent.
The application period is from May 1 to July 3, 2017.
Research projects should aim to provide information that could directly advance the use of pharmacotherapy for treating users of any nicotine or tobacco product in clinical practice. Examples could include:
Non-human studies and educational programs fall outside of the scope of the GRAND program for 2017 and will not be considered for an Award.
Examples of other topics that fall outside of the scope of the GRAND program for 2017 and will not be considered for an Award, unless directly related to advancing the use of pharmacotherapy, include:
This year, the GRAND program is supporting the Nicotine & Tobacco Research journal to pilot a new initiative in which studies can be accepted based on their methods. Applicants will be asked if they would like to opt into this pilot. For additional details click here
If uncertain whether or not your topic is within scope, please contact the GRAND Program Coordinator (Email: email@example.com. Email messages will receive a reply within 2 business days)